Eli Lilly and Company (LLY)
NYSE • Healthcare
November 17, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Eli Lilly and Company keeps $26 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 3
in 77 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Eli Lilly beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $7.48 topping the $5.68 estimate (+31.7%) and revenue of $24.397 billion topping the $22.583 billion estimate (+8%). Revenue rose about 39% year over year to roughly $24.4 billion (up from about $17.6 billion a year ago), with sales concentrated in the U.S., where revenue climbed about 34% to roughly $15.1 billion, while Rest of world grew nearly 90% to about $3.2 billion and China increased about 69% to roughly $947 million. Profitability remained elevated, with operating income of about $8.9 billion translating to an operating margin of roughly 37%. Net income rose about 16% year over year to roughly $6.5 billion (up from about $5.6 billion a year ago). Lilly generated about $11.4 billion of operating cash flow during the quarter and returned cash through roughly $377 million of share repurchases alongside about $1.5 billion in dividends. For the next period, consensus calls for EPS of $10.57 on revenue of $24.054 billion.
About Eli Lilly and Company
Eli Lilly and Company researches, develops, and commercializes human medicines, operating as a large pharmaceutical company listed on the NYSE as LLY. Its portfolio spans diabetes, oncology, immunology, neuroscience, and other specialty therapies, and it recorded $65.2 billion of revenue in FY2025.
Today's Snapshot
LLY closed 1.1% lower at 1415.43, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level. Eli Lilly won FDA approval for Retevmo, its cancer treatment.
Trading Volume
Below 10d avg (3.1M)
1.9M
vs S&P 500 Today
Moderate Outperformance
+0.22%
Updated: November 17, 2026 at 21:07 UTC
LLY Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1144.19 - $1410.87Buy
- RSI (14)63.02Neutral
- Stochastic %K (14, 3, 3)76.79Neutral
- MACD Level (12, 26)52.81Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.